Who
Blair Curtis Jackson
President & CEO, Alkermes plc
Company insider
Files Form 4 as: President & CEO, Alkermes plc, Alkermes.
In numbers
- Trades disclosed
- 134
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $2.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 16 Feb 2021
- Last trade
- 5 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Aug 2026filed 7 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —93,229 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —124,305 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —93,229 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —124,305 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —94,900 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —44,078 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —94,900 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —44,078 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —8,322 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $114K3,695 at $30.73 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,322 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,322 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —8,322 | filing |
| 26 Feb 2026filed 27 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $114K3,695 at $30.73 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —8,738 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $125K3,880 at $32.19 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,738 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,738 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —8,738 | filing |
| 23 Feb 2026filed 25 Feb 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $125K3,880 at $32.19 | filing |
News
Traders Buy High Volume of Put Options on Alkermes (NASDAQ:ALKS)ALKS · tickerreport.com · 17 Oct 2026Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)ALKS · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Blair Curtis Jackson; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.